Ultragenyx Pharmaceutical Inc.: UBS initiates coverage with neutral rating and $16 target price
RARE•UBS initiated coverage of Ultragenyx Pharmaceutical Inc. with a neutral rating and a $16 target price.
Related News
Better names former X CEO Linda Yaccarino independent director
BETR•
Anglo American chief says tech giants reportedly eye stakes to secure metals supply
NGLOY•
AI boom stumbles over white swan events
CRWV•
Revolution Medicines wins EU committee backing for pancreatic cancer treatment
RVMD•
Oshkosh to announce third-quarter earnings
OSK•